New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 1, 2014
16:37 EDTANIP, SHPGANI Pharmaceuticals acquires U.S. rights for Vancocin from Shire
ANI Pharmaceuticals (ANIP) announced that it has acquired the U.S. rights for Vancocin 125 mg and 250 mg capsules from Shire (SHPG). In addition, ANI acquired from Shire approved ANDAs for the currently non-marketed products vancomycin hydrochloride injectable 500 mg, 1 gm and 10 gm and vancomycin hydrochloride oral solution 250 mg and 500 mg. ANI paid $11M in cash for the rights to Vancocin together with existing inventories on hand. Following a transition period, ANI intends to launch Vancocin capsules under its own label during the fourth quarter. The transaction is immediately accretive and sales of Vancocin capsules are expected to generate approximately $5.4M in revenues and $4M in non-GAAP EBITDA annually.
News For ANIP;SHPG From The Last 14 Days
Check below for free stories on ANIP;SHPG the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 17, 2014
07:43 EDTSHPGBofA/Merrill to hold a conference
Subscribe for More Information
September 16, 2014
11:51 EDTSHPGOECD looks to close tax loopholes with new proposals
Subscribe for More Information
September 15, 2014
10:55 EDTSHPGRegulators to determine AbbVie, Shire deal by next month, Reuters says
Subscribe for More Information
08:01 EDTSHPGShire announces FDA acceptance for filing of sNDA for Vyvanse
Subscribe for More Information
September 10, 2014
08:37 EDTSHPGMedgenics appoints Scott Applebaum as Chief Legal Officer
Subscribe for More Information
07:06 EDTSHPGSangamo plans to submit IND application for hemophilia B in 2Q15
Sangamo BioSciences (SGMO) plans to submit an Investigational New Drug application for the treatment of hemophilia B in Q2 2015. This program, partnered with Shire (SHPG), is the first therapeutic application of Sangamo's zinc finger nuclease-mediated In Vivo Protein Replacement Platform. Sangamo is developing the IVPRP as a generally applicable strategy to provide a one-time, permanent genetic cure for monogenic diseases that are currently managed by protein replacement therapy, which involves costly repeat infusions over the lifetime of the patient.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use